Kura Oncology, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (see signature page)
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Troy E. Wilson, Ph.D., J.D. and Thomas Doyle, and each of them, as his or her true and lawful attorneys-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Troy E. Wilson, Ph.D., J.D. | President, Chief Executive Officer and Chairman of the Board of Directors | March 5, 2026 |
| Troy E. Wilson, Ph.D., J.D. | (Principal Executive and Financial Officer) | |
| /s/ Thomas Doyle | Senior Vice President, Finance & Accounting | March 5, 2026 |
| Thomas Doyle | (Principal Accounting Officer) | |
| /s/ Helen Collins, M.D. | Director | March 5, 2026 |
| Helen Collins, M.D. | ||
| /s/ Faheem Hasnain | Director | March 5, 2026 |
| Faheem Hasnain | ||
| /s/ Thomas Malley | Director | March 5, 2026 |
| Thomas Malley | ||
| /s/ Diane Parks | Director | March 5, 2026 |
| Diane Parks | ||
| /s/ Carol Schafer | Director | March 5, 2026 |
| Carol Schafer | ||
| /s/ Mary Szela | Director | March 5, 2026 |
| Mary Szela | ||
| /s/ Michael Vasconcelles, M.D. | Director | March 5, 2026 |
| Michael Vasconcelles, M.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.